ClinicalTrials.gov
ClinicalTrials.gov Menu

A Blood Stem Cell Transplant for Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03249831
Recruitment Status : Recruiting
First Posted : August 15, 2017
Last Update Posted : May 18, 2018
Sponsor:
Collaborator:
California Institute for Regenerative Medicine
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:

Blood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot).

Patients with sickle cell disease produce abnormal red blood cells. A blood stem cell transplant from a donor is a treatment option for patients with severe sickle cell disease. The donor can be healthy or have the sickle cell trait. The blood stem cell transplant will be given to the patient as an intravenous infusion (IV). The donor blood stem cells will then make normal red blood cells ─ as well as other types of blood cells ─ in the patient. When blood cells from two people co-exist in the patient, this is called mixed chimerism.

Most children are successfully treated with blood stem cells from a sibling (brother/sister) who completely shares their tissue type (full-matched donor). However, transplant is not an option for patients who (1) have serious medical problems, and/or (2) do not have a full-matched donor. Most patients will have a relative who shares half of their tissue type (e.g. parent, child, and brother/sister) and can be a donor (half-matched or haploidentical donor).

Adult patients with severe sickle cell disease were successfully treated with a half-matched transplant in a clinical study. Researchers would like to make half-matched transplant an option for more patients by (1) improving transplant success and (2) reducing transplanted-related complications.

This research transplant is being tested in this Pilot study for the first time. It is different from a standard transplant because:

  1. Half-matched related donors will be used, and
  2. A new combination of drugs (chemotherapy) that does not completely wipe out the bone marrow cells (non-myeloablative treatment) will be used to prepare the patient for transplant, and
  3. Most of the donor CD4+ T cells (a type of immune cells) will be removed (depleted) before giving the blood stem cell transplant to the patient to improve transplant outcomes.

It is hoped that the research transplant:

  1. Will reverse sickle cell disease and improve patient quality of life,
  2. Will reduce side effects and help the patient recover faster from the transplant,
  3. Help the patient keep the transplant longer and
  4. Reduce serious transplant-related complications.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Sickle Cell Disorder Hemoglobinopathies Thalassemia Anemia, Sickle Cell Drug: Cyclophosphamide Drug: Pentostatin Drug: Rabbit anti-thymocyte globulin Drug: Tacrolimus Drug: Mycophenolate mofetil Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Phase 1

Detailed Description:
This is a pilot study to determine the safety and feasibility of the COH-MC-17 regimen and ability of the regimen to induce a mixed chimeric status in severe sickle cell disease patients (hemoglobin SS or S-βº Thalassemia). The COH-MC-17 regimen consists of a non-myeloablative regimen (cyclophosphamide, pentostatin and rabbit-anti-thymocyte globulin (ATG)) followed by a CD4+ T-cell-depleted haploidentical hematopoietic cell transplant (HaploHCT).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Estimated Study Start Date : June 2018
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: COH-MC-17 and immunosuppressants

Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.

Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.

The minimally manipulated transplant product is manufactured using the CliniMACS device.

Drug: Cyclophosphamide
Orally daily
Other Name: Cytoxan
Drug: Pentostatin
Intravenous
Other Name: NIPENT
Drug: Rabbit anti-thymocyte globulin
Intravenous
Other Names:
  • Rabbit ATG
  • Thymoglobulin
Drug: Tacrolimus
Initially IV. If patient tolerates, convert to oral.
Other Name: PROGRAF®
Drug: Mycophenolate mofetil
IV or oral
Other Names:
  • MMF
  • CellCept®
  • Myfortic
Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Infusion
Other Names:
  • CD4+ T-cell depleted HaploHCT
  • CD4+ T-cell depleted hematopoietic progenitor cell (HPC) product



Primary Outcome Measures :
  1. Toxicity per NCI-Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Day -22 to 2 years post-transplant ]
  2. Unacceptable Toxicity at least possibly related to COH-MC-17 [ Time Frame: Day -22 to Day +60 post-transplant ]
  3. Mixed Chimerism defined as 30-90% donor cells [ Time Frame: Day +60 post-transplant ]
  4. Feasibility of producing an infusion ready CD4+ T-cell-depleted hematopoietic product [ Time Frame: From apheresis to Day 0 ]

Secondary Outcome Measures :
  1. Adverse events of Grade 3 or higher [ Time Frame: Up to 2 years post-transplant ]
  2. Neutrophil count ≥ 500/mm3, time to recovery [ Time Frame: Up to 2 years post-transplant ]
  3. Platelet count ≥ 20,000/mm3, time to recovery [ Time Frame: Up to 2 years post-transplant ]
  4. Marrow failure [ Time Frame: Up to 2 years post-transplant ]
  5. Sickle cell disease related complications [ Time Frame: Up to 2 years post-transplant ]
  6. Non-relapse mortality [ Time Frame: Up to 2 years post-transplant ]
  7. Acute Graft versus Host Disease per 1994 Keystone Consensus Criteria [ Time Frame: Day + 100 post-transplant ]
  8. Chronic Graft versus Host Disease per 2014 National Institutes of Health Consensus Criteria [ Time Frame: Day+ 180, + 1 year and +2 years post-transplant ]
  9. Overall Survival [ Time Frame: Up to 2 years post-transplant ]
  10. Disease-Free Survival [ Time Frame: Up to 2 years post-transplant ]
  11. Event-Free Survival [ Time Frame: Up to 2 years post-transplant ]
  12. Disease Relapse [ Time Frame: Up to 2 years post-transplant ]
  13. Persistent post-immunosuppressant mixed chimerism [ Time Frame: Up to 2 years post-transplant ]
    Between 5% and 95% donor chimerism at two years post- transplant, at least 6 months post- immunosuppressant

  14. Persistent immunosuppressant -dependent mixed chimerism [ Time Frame: +2 years post-transplant ]
    Between 5% and 95% donor chimerism at two years post- transplant and on immunosuppressant

  15. Complete chimerism: >95% donor chimerism [ Time Frame: +2 years post-transplant ]
  16. Primary donor graft failure: Defined as < 5% donor chimerism by Day + 30 post- transplant [ Time Frame: Day +30 post-transplant ]
  17. Secondary donor graft failure: Defined as < 5% donor chimerism beyond Day +30 in patients with prior documentation of ≥ 5% donor cells by Day +30 [ Time Frame: > Day + 30 up to 2 years post-transplant ]
  18. Donor chimerism in blood [ Time Frame: Day +30, Day +60, Day +100, Day+180, and +1 yr, +1.5 yr, +2yr post-transplant ]
  19. Donor chimerism in bone marrow [ Time Frame: Day + 100, Day + 180 and + 1 yr post-transplant ]
  20. Percent HbS levels [ Time Frame: Baseline, and then Day + 30, Day + 100, Day + 180, +1 yr, +1.5, +2yr post-transplant ]

Other Outcome Measures:
  1. Ratio donor: recipient de novo thymic T cells [ Time Frame: Up to 2 years post-transplant ]
  2. Ratio donor: recipient FoxP3+ regulatory T cells [ Time Frame: Up to 2 years post-transplant ]
  3. Tolerance status of donor: recipient type T cells [ Time Frame: Up to 2 years post-transplant ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  1. Confirmed diagnosis of hemoglobin SS or S-βº Thalassemia sickle cell disease
  2. Severe disease status as defined by presence of one or more of the following:

    1. Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; or increased transcranial Doppler velocity (>200 m/s). A stroke is defined as a sudden neurologic change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes.
    2. History of ≥ 1 episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea).
    3. History of ≥ 2 severe vaso-occlusive pain crises (VOC) per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility. Note that priapism that lasts more than 2 hours and requires care at a medical facility is also considered a VOC.
    4. Osteonecrosis of ≥ 2 joints despite the institution of supportive care measures.
    5. Prior treatment with regular RBC transfusion therapy, defined as receiving ≥ 8 transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
  3. No HLA matched sibling or 10/10 matched unrelated donor
  4. Related donor who:

    1. Is genotypically haploidentical on HLA-A, B, C and DRB1 loci AND
    2. Meets institutional criteria
  5. Failed prior hydroxyurea therapy or have intolerance to hydroxyurea
  6. Meets protocol specified organ function criteria
  7. Women of childbearing potential or sexually active male: Agreement to use adequate contraception prior to study entry and 6 months post-transplant.

Exclusion Criteria

  1. Prior stem cell transplant
  2. Prior bone marrow transplant
  3. Concurrent other investigational agents, chemotherapy, biological therapy or radiation therapy
  4. Planned use of moderate and strong CYP3A4 inhibitors
  5. Active infection
  6. Major surgery within the last 30 days
  7. Clinically significant liver fibrosis or cirrhosis if on chronic transfusion therapy > 6 months
  8. Active malignancy (other than non-melanoma skin cancers)
  9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen.
  10. Women of childbearing potential: pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03249831


Contacts
Contact: Joseph Rosenthal, MD 626-218-8442 jrosenthal@coh.org
Contact: Teresa Kim, RN 626-218-0263 teresakim@coh.org

Locations
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Joseph Rosenthal, MD    626-256-4673 ext 88442    jrosenthal@coh.org   
Principal Investigator: Joseph Rosenthal, MD         
Sponsors and Collaborators
City of Hope Medical Center
California Institute for Regenerative Medicine
Investigators
Principal Investigator: Joseph Rosenthal, MD City of Hope Medical Center

Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03249831     History of Changes
Other Study ID Numbers: 16453
First Posted: August 15, 2017    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by City of Hope Medical Center:
Sickle Cell Disease
Sickle Cell Disorders
Hemoglobinopathies
Thalassemia
Anemia, Sickle Cell
Haploidentical Transplant
Nonmyeloablative Conditioning
CD4+ T cell
CD4+ T cell-depleted Hematopoietic Cell Transplant
Mixed Chimerism

Additional relevant MeSH terms:
Anemia, Sickle Cell
Thalassemia
Hemoglobinopathies
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn
Cyclophosphamide
Tacrolimus
Thymoglobulin
Antilymphocyte Serum
Immunosuppressive Agents
Mycophenolic Acid
Pentostatin
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Calcineurin Inhibitors
Enzyme Inhibitors
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents